|
Diabetes Mellitus
|
0.070 |
Biomarker
|
group |
BEFREE |
FFAR4 has been considered as a potential target for metabolic diseases, including diabetes.
|
31580060 |
2019 |
|
Diabetes Mellitus
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Since PHS is rich in the plasma membrane of yeast, our results imply that PHS found in fermented food could have effects on anti-diabetes through activation of GPR120.
|
29373685 |
2018 |
|
Diabetes Mellitus
|
0.070 |
Biomarker
|
group |
BEFREE |
Since FFA4 is currently an attractive drug target for treatment of metabolic disorders such as diabetes and obesity, understanding its role in cancer progression is critical towards the drug discovery process.
|
29452095 |
2018 |
|
Diabetes Mellitus
|
0.070 |
Biomarker
|
group |
BEFREE |
In addition, GPR120 KO mice develop obesity, increased inflammation, and insulin resistance, consistent with a role for GPR120 signaling in the metabolic syndrome and diabetes mellitus.
|
22560206 |
2012 |
|
Diabetes Mellitus
|
0.070 |
Biomarker
|
group |
BEFREE |
GPR120 agonists have therapeutic potential for the treatment of diabetes, but few selective agonists have been reported.
|
28374589 |
2017 |
|
Diabetes Mellitus
|
0.070 |
Biomarker
|
group |
BEFREE |
Therefore, GPR120, the sensing receptor for long-chain free fatty acids, represents a novel drug target for the treatment of obesity and diabetes.
|
23317787 |
2013 |
|
Diabetes Mellitus
|
0.070 |
Biomarker
|
group |
BEFREE |
These findings indicate that GPR120 activation is protective against lipotoxicity-induced pancreatic β-cell dysfunction, via the mediation of PDX1 expression and inhibition of islet inflammation, and that GPR120 activation may serve as a preventative and therapeutic target for obesity and diabetes.
|
30523046 |
2019 |
|
Metabolic Diseases
|
0.070 |
Biomarker
|
group |
BEFREE |
Since FFA4 is currently an attractive drug target for treatment of metabolic disorders such as diabetes and obesity, understanding its role in cancer progression is critical towards the drug discovery process.
|
29452095 |
2018 |
|
Metabolic Diseases
|
0.070 |
AlteredExpression
|
group |
BEFREE |
GPR120, which is activated by long-chain free fatty acids (FFAs), has been recognized as a new attractive target for the treatment of type 2 diabetes and metabolic disease.
|
28435531 |
2017 |
|
Metabolic Diseases
|
0.070 |
Biomarker
|
group |
BEFREE |
FFAR4 has been considered as a potential target for metabolic diseases, including diabetes.
|
31580060 |
2019 |
|
Metabolic Diseases
|
0.070 |
Biomarker
|
group |
BEFREE |
GPR120 is a novel target for the treatment of metabolic disease and type 2 diabetes.
|
31691553 |
2019 |
|
Metabolic Diseases
|
0.070 |
Biomarker
|
group |
BEFREE |
G protein-coupled receptor 120 (GPR120) represents a promising target for the treatment of obesity-related metabolic disorders for its involvement in the regulation of adipogenesis, inflammation, glucose uptake, and insulin resistance.
|
28285320 |
2017 |
|
Metabolic Diseases
|
0.070 |
Biomarker
|
group |
BEFREE |
GPR120/FFAR4 has been recognized as a functional fatty acid receptor and an attractive therapeutic target for metabolic diseases.
|
29221950 |
2018 |
|
Metabolic Diseases
|
0.070 |
Biomarker
|
group |
BEFREE |
Free-fatty acid receptor-4 (GPR120): Cellular and molecular function and its role in metabolic disorders.
|
26827942 |
2016 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Free fatty acid receptor 4 (FFAR4) is associated with the epithelial mesenchymal transition (EMT) and is involved in the progression of several types of cancer.
|
30248044 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our results establish a novel role of FFAR4 and its ligands in the complicated interactions between tissue lipid profile and cancer biology.
|
30795784 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
However, the distribution pattern of the receptor suggests that targeting FFA4 may also be useful in other conditions, ranging from cancer to lung function.
|
28734639 |
2017 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Therefore, GPR120 is expected to be a potential new target for cancer therapy.
|
30520776 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The role of free-fatty acid receptor-4 (FFA4) in human cancers and cancer cell lines.
|
29452095 |
2018 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Free fatty acid receptor 4 (FFAR4) is associated with the epithelial mesenchymal transition (EMT) and is involved in the progression of several types of cancer.
|
30248044 |
2018 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Therefore, GPR120 is expected to be a potential new target for cancer therapy.
|
30520776 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
The role of free-fatty acid receptor-4 (FFA4) in human cancers and cancer cell lines.
|
29452095 |
2018 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Our results establish a novel role of FFAR4 and its ligands in the complicated interactions between tissue lipid profile and cancer biology.
|
30795784 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
However, the distribution pattern of the receptor suggests that targeting FFA4 may also be useful in other conditions, ranging from cancer to lung function.
|
28734639 |
2017 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We investigated whether host or tumor GPR120 plays a role in the anti-prostate cancer effects of ω-3 FAs.
|
30202902 |
2019 |